Effectiveness of Short-Term Use Denosumab and Risedronate Using β-Crosslaps and Histopathology as a Parameter in Osteoporotic Rat Model
Osteoporosis is a condition of decreased bone mass density. Pharmacological management uses drugs that decrease bone resorption or increase bone formation. The most commonly used drugs are bisphosphonates. Risedronate is one of these bisphosphonates. It inhibits osteoclasts, resulting in osteoclast...
Saved in:
| Main Authors: | Afrisya Bimo Siwendro, Ahmad Ramdan, Yoyos Dias Ismiarto, Anglita Yantisetiasti, Dliyauddin fachri |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universitas Padjajaran
2024-09-01
|
| Series: | Majalah Kedokteran Bandung |
| Subjects: | |
| Online Access: | https://journal.fk.unpad.ac.id/index.php/mkb/article/view/3016 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
THE EFFECTIVENESS OF ZINC AND RISEDRONATE ON BONE TURNOVER IN RAT MODEL OF OSTEOPOROSIS ASSESSED WITH THE EXPRESSION OF β-CROSSLAPS
by: Adam Fajar, et al.
Published: (2019-12-01) -
The efficacy and safety of denosumab, risedronate, alendronate and teriparatide to treat male osteoporosis: a systematic review and bayesian network meta-analysis
by: Shu Jun Chai, et al.
Published: (2025-06-01) -
Immunological enhancement of micro-nanoparticle formulated with risedronate and zinc as vaccine adjuvant in aged mice
by: Yue Liu, et al.
Published: (2025-05-01) -
A study evaluating the risk factors and different treatment modalities for osteoporosis
by: Priya Madhuri Paspula, et al.
Published: (2025-03-01) -
Denosumab is the first gene engineered agent for the treatment of osteoporosis
by: O A Nikitinskaya, et al.
Published: (2012-09-01)